Diabetes Mellitus, Diabetic Kidney Disease Diabetes Mellitus, Blood Glucose Control, Diabetic Kidney Disease, Dipeptidyl Peptidase 4 Inhibitor Sodium-Glucose Transporter 2 Inhibitor
Conditions
Interventions
Patients in this arm will receive a once-daily, oral, fixed dose (5mg) of Linagliptin in tablet form for a period of 3 months.,Patients in this arm will receive a once-daily, oral, fixed dose (25mg) o
Active Comparator Drug,Active Comparator Drug
Linagliptin Group,Empagliflozin Group
Sponsors
Pak Emirates Military Hospital Rawalpindi
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. A urinary albumin to creatinine ratio between 30 and 3000 mg/g, or albuminuria greater than 30 mg/L of urine or greater than 30 mcg/min 2. Having diabetes mellitus type 2 3. Previously have not used Dipeptidyl Peptidase 4 Inhibitor and Sodium-Glucose Transporter-2 Inhibitor 4. Glycosylated hemoglobin between 6.5% - 10.0% 5. Estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m2
Exclusion criteria
Exclusion criteria: 1. Non-diabetic kidney disease, 2. renal transplant 3. Presence of urinary tract infection 4. Cardiovascular event or transient ischemic attack or stroke within the previous 3 months 5. Hypersensitivity to Dipeptidyl Peptidase 4 Inhibitor or Sodium-Glucose Transporter-2 Inhibitor 6. Not willing to participate 7. Pregnant females 8. Uncontrolled hyperglycaemia 9. Anti-obesity treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycaemic Control At 12 weeks Glycosylated Haemoglobin | — |
Secondary
| Measure | Time frame |
|---|---|
| Renal Dysfunction At 12 Weeks eGFR,Renal Dysnfunction At 12 weeks Albuminuria | — |
Countries
Pakistan
Contacts
Public ContactUmar Mirza
Pak Emirates Military Hospital
Outcome results
None listed